Clinical Trials Sponsored by Hengrui Therapeutics, Inc.

Total 2993 results

Onconova Therapeutics, Inc.

Completed

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Neoplasms | Cancer | Advanced Cancer | Solid Tumors

United States
Onconova Therapeutics, Inc.

Withdrawn

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Asthma

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
Elcelyx Therapeutics, Inc.

Completed

Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks

Type 2 Diabetes Mellitus
Leap Therapeutics, Inc.

Completed

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Intrepid Therapeutics, Inc.

Completed

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

Androgenetic Alopecia

United States
Melinta Therapeutics, Inc.

Completed

Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Community-Acquired Bacterial Pneumonia

United States, Canada
Orexigen Therapeutics, Inc

Terminated

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Obesity | Overweight

United States
Vyne Therapeutics Inc.

Completed

Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea (EMIRA)

Rosacea | Papulopustular Rosacea

Germany
BlackThorn Therapeutics, Inc.

Completed

A Study of LY2940094 in Major Depressive Disorder

Major Depressive Disorder

Canada
Nivalis Therapeutics, Inc.

Completed

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9) ((SNO-9))

Cystic Fibrosis

United States
Cara Therapeutics, Inc.

Completed

A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

Osteoarthritis

United States
Alcresta Therapeutics, Inc.

Completed

Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

Exocrine Pancreatic Insufficiency

United States
Nivalis Therapeutics, Inc.

Unknown

Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor (SNO-7)

Cystic Fibrosis

United States
Nivalis Therapeutics, Inc.

Completed

PK Study of N91115 in Cystic Fibrosis Patients (SNO3)

Cystic Fibrosis

United States
Mast Therapeutics, Inc.

Completed

Evaluation of Repeat Administration of Purified Poloxamer 188 (EPIC-E)

Sickle Cell Disease

United States
Carbylan Therapeutics, Inc.

Completed

Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis

Osteoarthritis of the Knee

Canada, Australia, Netherlands Antilles
Cara Therapeutics, Inc.

Completed

Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus

Pruritus | Uremic Pruritus

United States
Revance Therapeutics, Inc.

Completed

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis

Hyperhidrosis

United States
Lisata Therapeutics, Inc.

Completed

NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction (PreSERVE-AMI)

ST Segment Elevation Myocardial Infarction

United States
Sorrento Therapeutics, Inc.

Completed

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

United States, Georgia, Moldova, Republic of, Romania, Serbia, Singapore, Ukraine
Opexa Therapeutics, Inc.

Terminated

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis (OLTERMS)

Clinically Isolated Syndrome | Multiple Sclerosis, Relapsing-Remitting

United States
INSYS Therapeutics Inc

Completed

Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers

Healthy

United States
Topokine Therapeutics, Inc.

Completed

Phase 1 Study of XAF5 Gel Applied to Skin of Healthy Volunteers

Healthy
Orexigen Therapeutics, Inc

Completed

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

Obesity | Overweight

United States
Onconova Therapeutics, Inc.

Terminated

Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia

Lymphoma | Acute Lymphocytic Leukemia

United States
INSYS Therapeutics Inc

Completed

Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects

Pharmacokinetics and Pharmacodynamics

United States
CymaBay Therapeutics, Inc.

Completed

Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

Gout

United States, Canada, Georgia
Mirati Therapeutics Inc.

Terminated

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

United States, Canada
Mirati Therapeutics Inc.

Completed

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, Canada
Mirati Therapeutics Inc.

Completed

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Lymphoma

United States, Canada
PNP Therapeutics, Inc.

Completed

Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors

Head and Neck Cancer

United States
Repros Therapeutics Inc.

Completed

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Tobira Therapeutics, Inc.

Completed

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

Healthy

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

Acute Pain

United States
Mirati Therapeutics Inc.

Terminated

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States, Canada, United Kingdom
CymaBay Therapeutics, Inc.

Completed

Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin

Type 2 Diabetes

United States, Israel, Argentina, India
Cara Therapeutics, Inc.

Completed

A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery

Acute Pain

United States
Melinta Therapeutics, Inc.

Completed

Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

Hepatic Impairment

United States
CymaBay Therapeutics, Inc.

Completed

Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

Hyperuricemia | Gout

United States
Omnitura Therapeutics, Inc.

Completed

A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas

Neoplasms

Canada
CymaBay Therapeutics, Inc.

Completed

Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients

Hyperuricemia | Gout

United States
Nivalis Therapeutics, Inc.

Completed

A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

Healthy

United States
Mirati Therapeutics Inc.

Terminated

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Stomach Cancer | Breast Cancer | Gastric Cancer | Lung Cancer | Prostate Cancer | Non-Small-Cell Lung Carcinoma | Prostatic Cancer | Pulmonary Cancer

United States
Orexigen Therapeutics, Inc

Completed

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

Healthy

United States
Orexigen Therapeutics, Inc

Completed

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

Obesity | Overweight

United States

3

Subscribe